Lemtrada

Lemtrada Overdosage

alemtuzumab

Manufacturer:

Genzyme

Distributor:

DKSH
Full Prescribing Info
Overdosage
In controlled clinical trials two MS patients accidentally received up to 60 mg LEMTRADA (i.e., total dose for initial treatment course) in a single infusion and experienced serious reactions (headache, rash, and either hypotension or sinus tachycardia). Doses of LEMTRADA greater than those tested in clinical studies may increase the intensity and/or duration of infusion-associated adverse reactions or its immune effects.
There is no known antidote for alemtuzumab over dosage. Treatment consists of discontinuation of the medicinal product and supportive therapy.
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Sign up for free
Already a member? Sign in